La fosfodiesterasa 3A y la hipertensión arterial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.Una nueva mutación en el gen PDE3A causa hipertensión con braquidactilia. Este descubrimiento proporciona nuevos modelos animales y objetivos potenciales para el desarrollo de tratamientos antihipertensivos.
Área De La Ciencia
- Investigación cardiovascular
- La genética
- Biología molecular
Sus Antecedentes
- La presión arterial alta (hipertensión) es una de las principales causas mundiales de muerte cardiovascular.
- La hipertensión autosómica dominante con braquidactilia es una forma grave de hipertensión relacionada con la muerte prematura por accidente cerebrovascular.
- Investigaciones previas implicaron el gen de la fosfodiesterasa 3A (PDE3A), pero faltaban pruebas in vivo.
Objetivo Del Estudio
- Para investigar la base genética de la hipertensión con braquidactilia.
- Crear y analizar modelos in vivo del defecto genético identificado.
- Explorar los mecanismos moleculares subyacentes a la hipertensión asociada a la PDE3A.
Principales Métodos
- Mapeo y secuenciación genética para identificar mutaciones.
- Edición del gen CRISPR-Cas9 para crear modelos animales (ratas y ratones).
- Tecnología transgénica, inmunoblotación y estudios de interacción con proteínas para analizar la función de la PDE3A.
Principales Resultados
- Se identificó un nuevo punto de mutación en el gen PDE3A en pacientes con hipertensión con braquidactilia.
- Los modelos de ratas y ratones transgénicos generados por CRISPR-Cas9 recapitularon la condición humana.
- La PDE3A mutada mostró un aumento de la actividad, una alteración de la fosforilación y una mayor interacción con el 14-3-3θ, lo que condujo a la proliferación de células musculares lisas vasculares y a una alteración de la función vascular.
Conclusiones
- Las mutaciones en el gen PDE3A causan directamente la hipertensión al aumentar la resistencia vascular periférica.
- Los modelos animales desarrollados ofrecen herramientas valiosas para una mayor investigación de los mecanismos de la hipertensión.
- Estos hallazgos pueden allanar el camino para nuevas terapias antihipertensivas dirigidas a la señalización PDE3A.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...